Herbert F. Oettgen
#124,016
Most Influential Person Now
Herbert F. Oettgen's AcademicInfluence.com Rankings
Herbert F. Oettgenphilosophy Degrees
Philosophy
#5735
World Rank
#8624
Historical Rank
Logic
#2958
World Rank
#4042
Historical Rank
Herbert F. Oettgenbiology Degrees
Biology
#7713
World Rank
#10675
Historical Rank
Immunology
#421
World Rank
#437
Historical Rank
Download Badge
Philosophy Biology
Herbert F. Oettgen's Degrees
- Doctorate Medicine Harvard University
Why Is Herbert F. Oettgen Influential?
(Suggest an Edit or Addition)Herbert F. Oettgen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. (1985) (565)
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium (1988) (565)
- GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody (1982) (546)
- Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. (1980) (533)
- Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. (1978) (470)
- PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLS* (1966) (455)
- Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. (1976) (421)
- Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. (1983) (336)
- Inhibition of leukemias in man by L-asparaginase. (1967) (306)
- Tumor necrosis factor and the acute metabolic response to tissue injury in man. (1988) (296)
- Toxicity of E. coli L‐asparaginase in man (1970) (287)
- Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. (1995) (284)
- Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. (1988) (271)
- The acute metabolic effects of tumor necrosis factor administration in humans. (1987) (245)
- Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon (1984) (238)
- Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. (1987) (234)
- Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. (1988) (233)
- Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. (1986) (230)
- T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. (1984) (229)
- Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. (1986) (228)
- Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens (1981) (219)
- Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens (1976) (218)
- Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients (2006) (218)
- GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. (1995) (216)
- Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. (1979) (212)
- Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. (1988) (208)
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. (1987) (208)
- Expression of T-cell differentiation antigens on effector cells in cell- mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells (1975) (202)
- Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. (1986) (200)
- GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. (1994) (184)
- Serological analysis of cell surface antigens of malignant human brain tumors. (1978) (184)
- Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. (1992) (182)
- E. coli L‐asparaginase in the treatment of leukemia and solid tumors in 131 children (1970) (178)
- Ly antigens as markers for functionally distinct subpopulations of thymus-derived lymphocytes of the mouse (1975) (176)
- Generation of human monoclonal antibodies reactive with cellular antigens. (1983) (168)
- Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. (1988) (164)
- T-cell deficiency in patients with squamous cell cancer of the head and neck. (1975) (163)
- Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. (1985) (159)
- Cell surface antigens of human renal cancer defined by autologous typing (1979) (157)
- Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. (1981) (148)
- Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. (1975) (138)
- Effect of intravesical bacillus calmette‐guerin (BCG) on carcinoma in situ of the bladder (1983) (133)
- Human melanoma antigen AH is an autoantigenic ganglioside related to GD2 (1982) (132)
- Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. (1989) (129)
- Clinical results of treatment with E. coli L‐asparaginase in adults with leukemia, lymphoma, and solid tumors (1970) (127)
- Phase I trial of recombinant interferon gamma in cancer patients. (1986) (123)
- Serologic approaches to the study of cancer in animals and in man. (1968) (118)
- Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors. (1985) (117)
- Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics (1977) (116)
- Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. (1985) (114)
- Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma (1983) (110)
- Cytotoxicity of lymphocytes from patients with cancer of the urinary bladder: Detection by A 3H‐proline microcytotoxicity test (1974) (110)
- Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. (1986) (109)
- High-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. (1985) (105)
- Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors (1972) (102)
- Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial (1985) (97)
- A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. (1990) (97)
- Macrophage factor controlling differentiation of B cells. (1979) (96)
- Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. (1986) (93)
- Cell-surface antigens of melanoma recognized by human monoclonal antibodies. (1987) (91)
- A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms. (1978) (90)
- Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. (1968) (88)
- Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. (1985) (88)
- The acute and chronic effects of alcohol on the human immune system. (1975) (87)
- Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. (1992) (87)
- Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. (1987) (84)
- Delayed Hypersensitivity and Transplantation Immunity elicited by Soluble Antigens of Chemically Induced Tumours in Inbred Guinea-pigs (1968) (83)
- A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. (1986) (81)
- Delayed-Hypersensitivity Reactions in Patients with Cancer (1974) (79)
- Blood group and blood‐group‐related antigens in normal pancreas and pancreas cancer: Enhanced expression of precursor type 1, Tn and Sialyl‐Tn in pancreas cancer (1991) (79)
- Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors (1986) (79)
- Treatment of malignant melanoma by intratumoral injection of BCG. (1973) (78)
- Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck. (1974) (76)
- Somatic cell genetic analysis of human cell surface antigens: chromosomal assignments and regulation of expression in rodent-human hybrid cells. (1984) (74)
- Ly phenotype of cytotoxic T cells for syngeneic tumor (1976) (73)
- Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. (1989) (73)
- Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma (1991) (72)
- Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody (1984) (66)
- Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. (1980) (66)
- Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. (1987) (66)
- Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. (1984) (65)
- Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. (1994) (65)
- Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. (1984) (65)
- Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. (1989) (65)
- Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. (1990) (64)
- Hybridomas in Cancer Diagnosis and Treatment (1982) (64)
- Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. (1987) (63)
- Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells (1985) (63)
- Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity. (1979) (62)
- Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. (1989) (60)
- Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. (1986) (60)
- Immunologic evaluation and prognosis in patients with head and neck cancer. (1977) (59)
- B-cell activation by lipopolysaccharide. Distinct pathways for induction of mitosis and antibody production (1977) (59)
- Alloantigen-induced T-cell proliferation: Lyt phenotype of responding cells and blocking of proliferation by Lyt antisera. (1980) (59)
- Expression of tag‐72 in normal colon, transitional mucosa, and colon cancer (1989) (58)
- L‐asparaginase activity in plasma and other biological fluids (1970) (58)
- Effects of dialyzable transfer factor in patients with breast cancer. (1974) (57)
- Human tumor immunology. (1971) (57)
- A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. (1992) (56)
- Hypofibrinogenemia due to L-asparaginase: studies of fibrinogen survival using autologous 131-I-fibrinogen. (1970) (55)
- Deficient cell‐mediated immunity in head and neck cancer patients secondary to autologous suppressive immune cells (1978) (55)
- Cell‐mediated cytotoxicity for cultured autologous melanoma cells (1979) (53)
- The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. (1990) (53)
- ON THE NUMBER AND NATURE OF ANTIGEN-SENSITIVE LYMPHOCYTES IN THE BLOOD OF DELAYED-HYPERSENSITIVE HUMAN DONORS (1971) (51)
- Phase I trials of poly(I,C) complexes in advanced cancer. (1985) (51)
- Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies. (1988) (51)
- Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. (1995) (49)
- Production of Antibody to Sheep Red Blood Cells by Human Tonsil Cells in vitro (1973) (48)
- Malignant lymphoma involving the jaw in African children: Treatment with methotrexate (1963) (48)
- Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies (1985) (47)
- Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells (1983) (47)
- Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. (1990) (46)
- Immunohistologic dissection of the human kidney using monoclonal antibodies. (1985) (46)
- Antigen-specific and polyclonal B-cell responses in patients with acquired immunodeficiency disease syndrome. (1986) (44)
- Effect of total-body irradiation on the transplantability of mouse leukemias. (1960) (43)
- Treatment of Cancer with Immunomodulators: Corynebacterium parvum and Levamisole (1976) (42)
- Treatment with high dose mouse monoclonal (anti‐GD3) antibody R24 in patients with metastatic melanoma (1992) (42)
- Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma (1995) (42)
- Experimental and Clinical Effects of L-Asparaginase (1970) (42)
- Immune reactivity in primary carcinoma of the lung and its relation to prognosis. (1976) (41)
- Ly antigens: markers of T cell function on mouse spleen cells. (1975) (40)
- Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. (1987) (40)
- Induction and immunological properties of tumor necrosis factor. (1978) (40)
- Monitoring intravesical bacillus Calmette‐Guerin treatment of superficial bladder carcinoma by serial flow cytometry (1986) (40)
- Prelabeling target cells with 3 H-proline as a method for studying lymphocyte cytotoxicity. (1973) (39)
- Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. (1989) (39)
- Endotoxin-induced tumor necrosis factor. (1980) (39)
- The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines (1985) (39)
- Mouse monoclonal IgM antibody against human lung cancer line SK-LC-3 with specificity for H(O) blood group antigen. (1982) (38)
- Intralesional injection of the methanol extraction residue of bacillus calmette‐guerin (MER) into cutaneous metastases of malignant melanoma (1978) (38)
- Characterization of two newly established human cell lines from patients with large‐cell anaplastic lung carcinoma (1982) (37)
- DEMONSTRATION OF DELAYED HYPERSENSITIVITY TO SOLUBLE ANTIGENS OF CHEMICALLY INDUCED TUMORS BY INHIBITION OF MACROPHAGE MIGRATION (1969) (37)
- DELAYED CUTANEOUS HYPERSENSITIVITY REACTIONS AND PROGNOSIS IN PATIENTS WITH CANCER (1976) (37)
- Characterization of interleukin 2-dependent cytotoxic T-cell clones: specificity, cell surface phenotype, and susceptibility to blocking by Lyt antisera. (1983) (37)
- Suppression and enhancement of the T cell-dependent production of antibody to SRBC in vitro by bacterial lipopolysaccharide. (1975) (37)
- Treatment of Bowen's disease with topical dinitrochlorobenzene and 5‐fluorouracil (1976) (35)
- Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial (1996) (35)
- Stimulation of human tonsillar lymphocytes in vitro. (1966) (35)
- RANDOMIZED TRIAL OF BACILLUS CALMETTE‐GUÉRIN (PERCUTANEOUS ADMINISTRATION) AS SURGICAL ADJUVANT IMMUNOTHERAPY FOR PATIENTS WITH STAGE‐II MELANOMA (1976) (35)
- Treatment of immunodeficiency with interleukin-2: initial exploration. (1984) (34)
- Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. (1990) (34)
- Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. (1988) (34)
- Serum containing endotoxin-induced tumour necrosis factor substitutes for helper T cells (1976) (34)
- Endotoxin‐induced in vitro release of interleukin‐1 by cancer patients' monocytes: Relation to stage of disease (1983) (33)
- Immunologic reactivity in patients with primary operable breast cancer (1978) (33)
- Gangliosides and cancer (1989) (33)
- Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. (1986) (31)
- Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. (1978) (31)
- Immunobiology of Operable Breast Cancer: An Assessment of Biologic Risk by Immunoparameters (1976) (29)
- Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells (1982) (29)
- CEA-like material in fluid from benign cysts of the breast. (1974) (29)
- Immunologic reactivity and prognosis in breast cancer (1980) (28)
- Macrophage requirements of CR- and CR+ B lymphocytes for antibody production in vitro. (1976) (28)
- Malignant lymphoma involving the jaw in African children: treatment with alkylating agents and actinomycin D. (1963) (28)
- Immunologic factors involved in the growth of primary tumors in human or animal hosts (1969) (28)
- Immunotherapy of cancer. (1977) (28)
- Monitoring intravesical bacillus Calmette-Guerin treatment of bladder carcinoma with flow cytometry. (1985) (27)
- In vivo localization of cloned IL-2-dependent T cells. (1983) (27)
- Immunocompetence testing in patients with one of the four common operable cancers--a review. (1978) (27)
- Unexpected toxicity from radiation therapy in two patients with Kaposi's sarcoma receiving interferon. (1985) (26)
- Surgical adjuvant therapy of malignant melanoma with Corynebacterium parvum (1981) (26)
- Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems. (1989) (26)
- American Cancer Society Phase I Trial of Naturally Produced β-Interferon (1984) (26)
- Mechanisms of Immunopotentiation (1977) (26)
- RECOMBINANT LEUKOCYTE A INTERFERON IN KAPOSI'S SARCOMA a (1984) (25)
- A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cells (1988) (25)
- Hexose Content of Guinea Pig γ1 and γ2 Immunoglobulins.∗ (1965) (24)
- Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective. (1983) (24)
- Demonstration of delayed hypersensitivity to soluble antigens of chemically induced tumors by inhibition of macrophage migration. (1970) (24)
- Regulation of the immune response. V. Antibody‐mediated inhibition of T and B cell cooperation in the in vitro response to red cell antigens (1974) (24)
- A phase II trial of high‐dose cisplatin and dacarbazine. Lack of efficacy of high‐dose, cisplatin‐based therapy for metastatic melanoma (1991) (23)
- Cytotoxic reactions of murine lymphoid cells studied with a tritiated proline microcytotoxicity test. (1975) (23)
- Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2. (1984) (22)
- Endotoxin-induced serum factor controlling differentiation of bone-marrow-derived lymphocytes. (1977) (22)
- [Immunobiology of cancer]. (1973) (20)
- Definition of an antigenic system associated with Burkitt's lymphoma. (1967) (20)
- Workshop in human tumor immunology. (1972) (20)
- Analysis of human monoclonal antibodies derived from lymphocytes of patients with cancer. (1984) (20)
- Clinical experience with L-asparaginase. (1970) (19)
- NHL‐3 protocol six‐drug combination chemotherapy for non‐hodgkin's lymphoma (1984) (18)
- Two cell-surface markers for human chromosome 1 in interspecies hybrids (1984) (18)
- Human Cancer Immunology (1980) (18)
- Intravenous corynebacterium parvum. An adjunct to chemotherapy for resistant advanced ovarian cancer (1977) (18)
- Anaphylactic antibody in the young rat. (1966) (18)
- Cytokines in clinical cancer therapy. (1991) (17)
- Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder. (1985) (17)
- Cyclic chemotherapy in lymphoma (1971) (17)
- The clinical utility of plasma and urinary carcinoembryonic antigen in patients with genitourinary disease. (1977) (17)
- Analysis of T cell subsets in cancer patients treated with interferon. (1983) (17)
- Use of the macrophage migration inhibition test to monitor fractionation of soluble antigens of chemically induced sarcomas of inbred guinea pigs. (1972) (17)
- High-dose Nitrogen Mustard Therapy with Intermittent Aortic Occlusion (1961) (16)
- Mouse monoclonal IgG 3 antibody detecting GD 3 ganglioside : A phase I trial in patients with malignant melanoma ( complement activation / inflammation / immunotherapy ) (2003) (16)
- Measurement of carcinoembryonic antigen. (1973) (16)
- Natural antibodies in human sera directed against blood‐group‐related determinants expressed on colon cancer cells (1983) (15)
- Problems of continuous chemotherapy by arterial catheters. (1963) (15)
- Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines. (2008) (15)
- Phase I Trial with the Interferon Inducer Poly I:C/Poly-L-Lysine (Poly ICL) (1983) (13)
- DNCB reactivity and prognosis in 419 patients with malignant melanoma (1981) (13)
- Antibody-dependent cell-mediated cytotoxicity for cultured autologous melanoma cells. (1981) (13)
- The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. (1985) (12)
- Cell surface antigens of murine leukemias induced by radiation leukemia virus. Recognition of individually distinct cell surface antigens by cytotoxic T cells on leukemias expressing crossreactive transplantation antigens (1986) (12)
- Surgical adjuvant therapy for malignant melanoma. (1981) (12)
- Effects of nicotinamide and related compounds on the antileukemic activity of 2-amino-1,3,4-thiadiazole. (1960) (12)
- The effect of various hormones on the serum level of anaphylactic antibody in the rat. (1966) (11)
- Suppression of T cell cytotoxicity by nude mouse spleen cells: reversal by monosaccharides and interleukin 2. (1983) (11)
- INFLUENCE OF POLY(A)·POLY(U) ON IMMUNE RESPONSE IN CANCER PATIENTS (1976) (11)
- Delayed hypersensitivity reactions in patients with carcinoma of the colon and rectum. (1977) (11)
- Treatment of acute nonlymphocytic leukemia in adults: Response to 2,2‐anhydro‐1‐B‐D‐Arabinofuranosyl‐5‐fluorocytosine and thioguanine on the L‐12 protocol (1981) (11)
- Cell surface antigen of human neuroblastomas is related to nuclear antigen of normal cells. (1985) (10)
- THE EFFECT OF ACTINOMYCINS AND THEIR DERIVATIVES ON A SPECTRUM OF TRANSPLANTED MOUSE LEUKEMIA * (1960) (10)
- Immunologic aspects of cancer. (1981) (10)
- Randomized trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. (1978) (9)
- Immunologic reactivity and prognosis in breast cancer. (1981) (9)
- Haemodynamic Effects of Occlusion of Abdominal Aorta During Nitorgen Mustard Therapy (1963) (9)
- Malignant lymphoma involving the jaw in African children: treatment with 2-chloro-4',4'-di-2-imidazolin-2-ylterephthalanilide dihydrochloride. (1963) (9)
- IFN-gamma-regulated expression of a differentiation antigen of human cells. (1988) (9)
- Treatment of AIDS-associated Kaposi's sarcoma with recombinant alpha interferon. (1986) (8)
- Comparison of carcinoembryonic antigen (CEA) methodologies. (1974) (8)
- Enhancement of tumor growth by graft-versus-host reaction. (1974) (8)
- CONTINUOUS INTRA-ARTERIAL OR INTRAVENOUS INFUSION OF 5-FLUORO-2-DEOXYURIDINE: THERAPEUTIC AND TOXIC EFFECTS. (1963) (8)
- Immunotherapy of colon cancer: Prospects for developing immunogenic vaccines based on autologous serological typing (1980) (8)
- Serolgic analysis of human cancer (1990) (8)
- Biological agents in cancer therapy: cytokines, monoclonal antibodies and vaccines (2005) (7)
- Interferons and other biological response modifiers in the treatment of Kaposi's sarcoma. (1985) (7)
- American cancer society Phase I trial of naturally produced beta-interferon. (1984) (7)
- Three human cell surface antigen systems determined by genes on chromosome 12 (1984) (7)
- Biological approaches to cancer therapy. (1989) (6)
- DESIGN OF PHASE‐I TRIALS OF IMMUNOPOTENTIATORS FOR CANCER THERAPY: LEVAMISOLE AND CORYNEBACTERIUM PARVUM * (1976) (6)
- Immunocompetence Testing in Patients with One of the Common Operable Cancer — A Review (1979) (6)
- Characterization of IL-2-dependent cytotoxic T-cell clones. II. Cell-surface phenotypes, histochemical and ultrastructural properties. (1983) (6)
- Effect of short‐term levamisole therapy on delayed hypersensitivity (1980) (5)
- Effects of transfer factor in patients with advanced cancer. (1978) (5)
- Immunotherapy with oral BCG and serial immune evaluation in childhood lymphoblastic leukemia following three years of chemotherapy (1980) (4)
- Excretion and tissue distribution of actinobolin. (1959) (4)
- Tumor-specific antigens. (1980) (4)
- Construction of Immunogenic GD3‐Conjugate Vaccines (1993) (4)
- Functional relationships of Lyt-2 and Lyt-3 expression and T-cell cytotoxicity: a new model system. (1985) (3)
- Serology of Cancer (1974) (3)
- Coproduction of interleukin-2 and interferon-gamma in human mononuclear cells. (1983) (3)
- HEXOSE CONTENT OF GUINEA PIG GAMMA-1 AND GAMMA-2 IMMUNOGLOBULINS. (1965) (3)
- Contributions to the treatment of cancer of the head and neck. Regional antimetabolite infusion. (1961) (3)
- L-Asparaginase: Current Status of Clinical Evaluation (1975) (2)
- Treatment of cancer with immunomodulators. (1976) (2)
- Levamisole as an immunoadjuvant: phase I study and application in breast cancer. (1978) (2)
- Cancer--achievements, challenges, and prospects for the 1980s : proceedings of the 1980 International Symposium on Cancer (1981) (2)
- Regulation of T-Cell Proliferation by Interleukin-2 in Male Homosexuals with Acquired Immune Deficiency Syndrome (1984) (2)
- Characterization of IL-2-dependent cytotoxic T-cell clones. III. Inhibition of killing activity by monosaccharides. (1983) (2)
- POTENTIATION OF THE ANTI-LEUKEMIC EFFECTS OF 2-AMINOTHIADIAZOLE BY ISONICOTINAMIDE AND DERIVATIVES. (1964) (2)
- In vivo inhibition of mouse leukemia by cytotoxic t-cell clones and exogenous il-2. Abstr. (1982) (2)
- [REGIONAL CHEMOTHERAPY OF MALIGNANT TUMORS. II. TREATMENT WITH MASSIVE DOSES OF NITROGEN MUSTARD WITH TEMPORARY COMPRESSION OF THE ABDOMINAL AORTA AND ITS COLLATERAL ARTERIES]. (1964) (2)
- Increased yields of IgG2a- and IgG3-secreting hybridomas after fusion of B cells from mice with autoimmune diseases. (1991) (2)
- Analysis of the Humoral Immune Repertoire in Patients with Cancer (1987) (1)
- Clinical Trial of Radiolabelled Monoclonal Antibody (mAb) Imaging in Patients with Metastatic Renal Cancer (1987) (1)
- Specificity and lyt phenotype of allospecific and tumor-specific cytotoxic t-cell lines after long term culture in interleukin 2 (il-2). Abstr. (1981) (1)
- Interferon in AIDS. (1987) (1)
- Clinical Trials of Human Leukocyte Interferon at the Memorial Sloan-Kettering Cancer Center (1982) (1)
- [Immunology in the diagnosis of cancer]. (1975) (1)
- [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy]. (1987) (1)
- Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer. (1977) (1)
- Phase I study of novo-pyrexal, a purified endotoxin preparation (1982) (1)
- Surface phenotype of nonadherent peritoneal cells effecting cell-mediated cytotoxicity in vitro for allogeneic and syngeneic murine sarcoma cells. (1976) (1)
- Biochemical and immunologic diagnosis of cancer. Functional histopathology. (1987) (1)
- Serological Dissection of Human Breast Cancer with Mouse and Human Monoclonal Antibodies (1985) (1)
- Tumor necrosis factor. (1987) (1)
- American Cancer Society Phase I Trial of Naturally Produced /i-Interferon1 (2006) (0)
- Multiple activities of IL-2-dependent T-cell clones☆☆☆ (1982) (0)
- Phase I Studies of Recombinant Tumor Necrosis Factor in Patients with Advanced Cancer (1988) (0)
- THE HUMORAL IMMUNE RESPONSE TO HUMAN CANCER1 (1985) (0)
- [The effect of glyoxal-bis (guanylhydrazone) on transplanted mouse leukemia]. (1959) (0)
- Heterogeneity of t cells. Different representations of ly alloan- tigens on killer cells and helper cells. (1975) (0)
- Stated Meeting of the New York Academy of Medicine: Presentation of the Academy Medal to Lloyd Old, M.D (1985) (0)
- Cancer immunology. (1980) (0)
- Cell Surface Molecules of Human Melanoma (2007) (0)
- Serologie Approaches to the Study of Cancer in Animals and in Man (2006) (0)
- Monoclonal antibodies against human kidney cancer antigens and procedures. (1984) (0)
- Ability of mouse leukemia. Abstr. (1960) (0)
- BCG in the therapy of cancer. (1975) (0)
- CEA-LikeMaterialinFluidfromBenignCystsof theBreast (1974) (0)
- Monoclonal antibodies and immobilized antibodies (1987) (0)
- Cell surface antigens of human malignant melanoma : Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells * ( serology / human cancer / tissue culture ) (2003) (0)
- Effects ofDialyzable Transfer Factor inPatients withBreast Cancer (1974) (0)
- Immunology and colonic cancer (1973) (0)
- Specific Active Immunization Against Cell Surface Antigens of Human Malignant Melanoma: Development of an Approach (1981) (0)
- Tumour-associated antigens defined by monoclonal antibodies (1988) (0)
- Subpopulations of cytotoxic t cells with different surface phenotypes. Abstr. (1975) (0)
- Expression of Lewis3, Lewis", X, and Y Blood Group Antigens in Human Colonie Tumors and Normal Tissue and in Human Tumor-derived Cell Lines1 (2006) (0)
- Delayed Hypersensitivity and Tumor Specific Immunity (1969) (0)
- [Inhibition of malignant human neoplasms with L-asparaginase]. (1969) (0)
- Renal Cell Carcinomas Specific Region of the Human Proximal Tubule and Subsets Analysis of a Mouse Monoclonal Antibody That Reacts with a Updated (2006) (0)
- High-Molecular-Weight Glycoproteins of Human Teratocarcinoma Defined by Monoclonal Antibodies to Carbohydrate Determinants 1 (2006) (0)
- [REGIONAL CHEMOTHERAPY OF MALIGNANT TUMORS. I. PROLONGED INTRA-ARTERIAL INFUSION OF ANTIMETABOLITES]. (1964) (0)
- In vivo migration of cloned il-2 dependent cytotoxic t cells. Abstr. (1982) (0)
- blood donors Blood donor Diagnosis Extent of disease Age Sex History of transfusion Carcinoma of bladder Carcinoma of bladder and 6 other primary tumors over past 50 yr Melanoma Carcinoma of bladder Carcinoma of bladder Melanoma (2007) (0)
- Phase I Clinical Studies of Tumor Necrosis Factor in Patients with Advanced Cancer (1990) (0)
- Effect of 4',4"-bis(2-imidazolin-2-ylamino)terephthalanilide dihydrochloride (NSC-53306) on immune response of the rat. (1965) (0)
- Treatment of Malignant Melanoma with a Mouse Monoclonal IgG3 Antibody Detecting the Ganglioside GD3 (1986) (0)
- [L-asparaginase: A new principle in the chemotherapy of malignant neoplasms]. (1969) (0)
- Antibody Reactivity to Cell Surface and IntraceUular Antigens (2003) (0)
- Melanoma tumor antigen and autologous antibody (1986) (0)
- CANCER DEFINED BY AUTOLOGOUS TYPING (1979) (0)
- THE CORRELATION BETWEEN TRANSPLANTED MOUSE AND HUMAN ACUTE LEUKEMIAS. (1964) (0)
- Corynebacterium parvum. (1976) (0)
- [Chronic acquired hemolytic anemia. Clinical and immunological studies on 47 cases]. (1959) (0)
- Transplanted mouse leukemia. (1960) (0)
- Production of interferon-alpha, beta and gamma by interleukin-2 dependent murine T-cell clones (1982) (0)
- Urine(or Both)of PatientswithCanceror BenignNeoplasms (1978) (0)
- Cell Surface Antigens of Radiation Leukemia Virus‐induced BALB/c Leukemias Defined by Syngeneic Cytotoxic T Lymphocytes (1989) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Herbert F. Oettgen?
Herbert F. Oettgen is affiliated with the following schools:
